IM | Jotup

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

Retrieved on:

月曜日, 5月 6, 2024

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.

Key Points:

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.
Our team is dedicated to turning the tide of the mental health crisis through our clinical-stage programs,” said Doug Drysdale, Chief Executive Officer of Cybin.
The BTD by the FDA validates CYB003's potential to show significant clinical improvements over existing treatments based on preliminary results and serves to expedite CYB003’s development pathway towards commercialization.
Cybin is also developing EMBARK for Clinical Trials (“EMBARKCT”), a scalable model of psychedelic facilitation training that will enable the Company to effectively screen, qualify, and train facilitators to participate in future pivotal trials.

SEC's Division of Investment Management to Host Second Annual Conference on Emerging Trends in Asset Management

Retrieved on:

水曜日, 4月 17, 2024

Investment management, Security (finance), Division, Conference, IM, Policy

Washington, D.C.--(Newsfile Corp. - April 17, 2024) - The Securities and Exchange Commission’s Division of Investment Management (IM) today announced it will host the second annual Conference on Emerging Trends in Asset Management on Thursday, May 16, 2024.

Key Points:

Washington, D.C.--(Newsfile Corp. - April 17, 2024) - The Securities and Exchange Commission’s Division of Investment Management (IM) today announced it will host the second annual Conference on Emerging Trends in Asset Management on Thursday, May 16, 2024.
The conference will bring together a variety of asset management industry participants, regulators, and academics to discuss emerging trends in asset management.
SEC Chair Gary Gensler, IM Division Director Natasha Vij Greiner, and Division staff will participate in the conference.
To learn more information about asset management and the work of the Division, please visit IM's webpage .

SL Green Realty Corp. Reports First Quarter 2024 EPS of $0.20 Per Share; and FFO of $3.07 Per Share

Retrieved on:

水曜日, 4月 17, 2024

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (the "Company") (NYSE: SLG) today reported a net income attributable to common stockholders for the quarter ended March 31, 2024 of $13.1 million, or $0.20 per share, as compared to a net loss of $39.7 million, or $0.63 per share, for the same quarter in 2023.

Key Points:

Signed 60 Manhattan office leases covering 633,660 square feet in the first quarter of 2024.
The acquisition is expected to close in the fourth quarter of 2024.
The sale is expected to close in the second quarter of 2024 and generate net proceeds of $20.0 million.
As of March 31, 2024, SL Green held interests in 57 buildings totaling 32.4 million square feet.

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Retrieved on:

水曜日, 4月 24, 2024

Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.

Key Points:

Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.
GARDP and Innoviva Specialty Therapeutics plan to submit the Phase 3 zoliflodacin data for future publication in a medical journal.
Oral zoliflodacin 3g was generally well tolerated and emergent adverse events were comparable between treatment arms (46.2% vs 46.4%).
Details for the ESCMID Global 2024 presentations are as follows:
Title: Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: results of a large global Phase 3 randomized controlled trial
Session: 05.

AvePoint's Inaugural AI and Information Management Report Reveals Organizations with Mature IM Strategies are 1.5x More Likely to Realize AI Benefits

Retrieved on:

水曜日, 4月 3, 2024

However, organizations with more mature information management (IM) strategies are 1.5x more likely to realize benefits from AI than those with less mature strategies.

Key Points:

However, organizations with more mature information management (IM) strategies are 1.5x more likely to realize benefits from AI than those with less mature strategies.
“If organizations don’t establish or adapt their information management strategies, the challenges they are already facing will be exacerbated by AI.
Organizations with mature IM strategies are 1.5x more likely to realize benefits from AI than those with less mature strategies.
To read the full AvePoint AI and Information Management Report, please visit avpt.co/AI-report-2024
AvePoint conducted its AI & Information Management study in collaboration with AIIM, an organization dedicated to advancing the information management industry, and with CIPL, a global privacy and data policy think and do tank, to better understand the intersection of AI and information management and how information management practices were impacting AI implementation.

Global and China L3/L4 Autonomous Driving and Startups Research Report 2024 Featuring Solutions of 15 OEMs and 21 Solutions of Tier1s and Startups - ResearchAndMarkets.com

Retrieved on:

火曜日, 4月 2, 2024

Technology, Autonomous Driving, Vehicles, Artificial Intelligence, Automotive, Cloud, Algorithm, Pony.ai, BYD, Data, Original equipment manufacturer, Mercedes-Benz, IM, WeRide, L2, Transport, Software, Geely, G9, City, Accident, OEM, BMW, NOA, Ecosystem, Mobility, Apolong, FAW, GAC Toyota, Arcfox, Baidu, L4, SAIC, GAC, L3

The "L3/L4 Autonomous Driving and Startups Research Report, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "L3/L4 Autonomous Driving and Startups Research Report, 2024" report has been added to ResearchAndMarkets.com's offering.
As China releases autonomous driving policies, the competition in intelligent driving is about to enter a new phase.
Suppliers working on L3/L4 autonomous driving, such as Baidu Apollo, Pony.ai and DeepRoute.ai, have started partnering with automakers to commercialize L2++ high-level driving assistance.
1 L3/L4 Autonomous Driving Policies, Regulations and Standards
4.1 Key Technologies for L4 Autonomous Driving: Algorithms
4.2 Key Technologies for L4 Autonomous Driving: Data Closed Loop
4.3 Key Technologies for L4 Autonomous Driving: Redundancy
4.4 Key Technologies for L4 Autonomous Driving: Vehicle-Road-Cloud Cooperation
4.5 Key Technologies for L4 Autonomous Driving: HD Maps and Positioning

International Master Alice Lee and Grandmaster Levon Aronian Win American Cup Women’s and Open Tournaments

Retrieved on:

火曜日, 3月 26, 2024

Sports, Electronic Games, Other Entertainment, Entertainment, Other Sports, Friends, GM, Saint Louis Chess Club, IM, American Cup, WGM, FIDE titles, Multimedia, Family

The 2024 American Cup is one for the history books as 14-year-old International Master (IM) Alice Lee clinched her first major tournament win, while Grandmaster (GM) Levon Aronian captured his first American Cup win and first victory as an American player in the Women’s and Open tournaments, respectively.

Key Points:

The 2024 American Cup is one for the history books as 14-year-old International Master (IM) Alice Lee clinched her first major tournament win, while Grandmaster (GM) Levon Aronian captured his first American Cup win and first victory as an American player in the Women’s and Open tournaments, respectively.
View the full release here: https://www.businesswire.com/news/home/20240326471285/en/
Fourteen-year-old International Master Alice Lee clinched her first major tournament win during the 2024 American Cup Women's Tournament hosted by the Saint Louis Chess Club at the World Chess Hall of Fame in St. Louis, Mo.
Playing a total of 12 games against GM Irina Krush, IM Alice Lee lost her first match against two-time American Cup Champion to come back in the Elimination Bracket.
For her efforts, Alice Lee won her first Women’s American Cup title and a check for $40,000.

Global and China Automotive Comfort System (Seating system, Air Conditioning System) Research Report 2024 Featuring Comfort Systems of 11 OEMs, 11 Seating System Suppliers, and 9 AC System Suppliers - ResearchAndMarkets.com

Retrieved on:

金曜日, 3月 15, 2024

Automotive comfort systems include seating system, air conditioning system, soundproof system and chassis suspension to improve comfort of drivers and passengers.

Key Points:

Automotive comfort systems include seating system, air conditioning system, soundproof system and chassis suspension to improve comfort of drivers and passengers.
This report highlights seating system and air conditioning system.
Air conditioning system: as the installation rate of heat pump air conditioners rises, air conditioning control systems become personalized, energy-efficient and active.
Heat pump air conditioner is an air conditioning system that integrates cooling and heating functions.

FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children

Retrieved on:

月曜日, 3月 11, 2024

Astellas Pharma, Capsule, New Drug Application, Patient, IM, Research, Infection, Azole, Marketing, FDA, Food, Pharmaceutical industry

NORTHBROOK, Ill., March 11, 2024 /PRNewswire/ -- Astellas Pharma US, Inc. (TSE: 4503, President: Mark Reisenauer, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug and pediatric exclusivity to CRESEMBA® (isavuconazonium sulfate) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. On December 8, 2023, CRESEMBA for injection was approved for pediatric patients 1 year of age and older and capsules for pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater.

Key Points:

On December 8, 2023, CRESEMBA for injection was approved for pediatric patients 1 year of age and older and capsules for pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater.
The FDA grants orphan drug exclusivity to orphan drugs that receive FDA marketing approval.
The FDA previously granted orphan drug exclusivity for CRESEMBA in 2015 for the treatment of IA and IM in adults.
"Astellas recognizes the importance of addressing significant unmet medical needs, especially for pediatric patients with rare and potentially life-threatening IA and IM infections.

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Retrieved on:

火曜日, 2月 20, 2024

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced topline results from its clinical study comparing repeat doses of neffy (epinephrine nasal spray) to repeat doses of epinephrine intramuscular (IM) injection, as requested by the FDA with and without nasal allergen challenge (NAC) conditions.

Key Points:

“The study objective was to compare twice dosing with epinephrine injection and twice dosing with neffy under normal conditions and after nasal allergen challenge.
With these results, we are completing the necessary work to submit our response to FDA in the next couple of months.
The repeat dose study under NAC conditions was designed with the FDA to address the Agency’s outstanding questions regarding neffy as described in the Complete Response Letter (CRL) from September 2023.
In addition, multiple PADAC members highlighted the favorable profile of neffy in our single dose NAC study.